Table 3.
The details of clinical trials of various Ayurvedic Rasayana drugs
| Herb | Study design | Primary outcome | CTRI details |
|---|---|---|---|
| Tinospora cordifolia (Guduchi) as single ingredient or in combination | Prospective non-randomized open label controlled interventional study | Incidence rate of COVID-19 infection | CTRI/2020/06/025525 |
| Randomized, parallel-group trial | Comparative assessment of incidence of COVID-19 | CTRI/2020/05/025488 | |
| Non-randomized, active controlled trial | Comparative assessment of occurrence of COVID-19 infection | CTRI/2020/05/025485 | |
| Non-randomized, multiple-arm trial | Comparative assessment of occurrence of COVID-19 infection | CTRI/2020/05/025385 | |
| Single-arm trial | Clinical cure rate: time to get a negative status of COVID-19 | CTRI/2020/05/025370 | |
| Single-arm trial | Incidence of COVID-19-positive cases as confirmed by RT-PCR | CTRI/2020/05/025213 | |
| Randomized, parallel-group trial | Comparative assessment of occurrence of COVID-19 infection in healthy volunteers | CTRI/2020/05/025088 | |
| Randomized, parallel-group trial | Improvement in bala (physical and mental health) of an individual |
CTRI/2020/05/025171 (part of whole regime/protocol) |
|
| Non-randomized, active controlled trial |
Percentage of patients progressing to serious/critical stage of disease Progress of disease as per clinical severity score Number of days taken to test negative for COVID, total days to discharge from hospital |
CTRI/2020/04/024882 (Guduchi and Piper longum and standard treatment) |
|
| Randomized, parallel-group trial | Improvement in bala | CTRI/2020/05/025178 | |
| Single-arm trial |
Efficacy in boosting Vyadhikshamatwa and prevention against communicable diseases. 2. Will help in overcoming the anxiety level and stress of HCQs |
CTRI/2020/05/025276 (multiple ingredient and haritki) |
|
| Randomized, parallel-group, active controlled trial |
1. Mean time (days) for clinical recovery 2. Proportion of patients showing clinical recovery |
CTRI/2020/06/025557 (Guduchi, Yastimadhu and Ayush 64) | |
| Randomized, parallel-group, placebo- controlled trial | Virological clearance as measured by RT-PCR of nasopharyngeal swab | CTRI/2020/05/025273 | |
| Single-arm trial | Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) | CTRI/2020/04/024731 | |
| Ashwagandha | Single arm trial | Incidence of COVID-19- positive cases (as confirmed by RT-PCR) |
CTRI/2020/05/025069 (Guduchi and Ashwagnadha and regime) |
| Randomized, parallel-group, placebo- controlled trial | Virological clearance as measured by RT-PCR of nasopharyngeal swab | CTRI/2020/05/025273 (Guduchi and Ashwagandha and regime | |
| Randomized, parallel-group trial | Comparative assessment of occurrence of COVID-19 infection | CTRI/2020/05/025166 | |
| Non-randomized, active controlled trial | Comparative assessment of occurrence of COVID-19 infection | CTRI/2020/05/025429 (combination) | |
| Randomized, parallel-group trial | Efficacy in the management of mild and asymptomatic cases of COVID-19 patients | CTRI/2020/05/025341 | |
| Single-arm trial |
1. Efficacy in boosting Vyadhikshamatwa and prevention against communicable diseases. 2. Will help in overcoming the anxiety level and stress of HCQs |
CTRI/2020/05/025398 | |
| Amla (Chyawanprash) | Randomized, parallel-group trial |
1. Comparative assessment of incidence of COVID-19 2. Comparative assessment of incidence of other non-COVID-19 infections |
CTRI/2020/05/024981 |
| Randomized, parallel-group trial | Percentage of participants with SARS-CoV-2 positivity as estimated by RT-PCR | CTRI/2020/05/025275 |